NOS1 and Alzheimer disease: Future work should isolate and quantify the major bioactive lipids, confirm their mechanisms through enzyme-kinetic and target-validation assays (ACHE/BChE, NOS1/NOS2, and arachidonic-pathway enzymes), and evaluate efficacy in AD-relevant cellular and animal models while assessing BBB permeability, pharmacokinetics, safety, and synergistic interactions among metabolites to clarify therapeutic feasibility.